These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21602551)

  • 41. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
    Irwin SM; Gruppo V; Brooks E; Gilliland J; Scherman M; Reichlen MJ; Leistikow R; Kramnik I; Nuermberger EL; Voskuil MI; Lenaerts AJ
    Antimicrob Agents Chemother; 2014 Jul; 58(7):4026-34. PubMed ID: 24798275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental ocular tuberculosis in guinea pigs.
    Rao NA; Albini TA; Kumaradas M; Pinn ML; Fraig MM; Karakousis PC
    Arch Ophthalmol; 2009 Sep; 127(9):1162-6. PubMed ID: 19752425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis.
    Miyata T; Cheigh CI; Casali N; Goodridge A; Marjanovic O; Kendall LV; Riley LW
    Vaccine; 2012 Jan; 30(2):459-65. PubMed ID: 22079078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
    Lanoix JP; Lenaerts AJ; Nuermberger EL
    Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
    Zhang N; Strydom N; Tyagi S; Soni H; Tasneen R; Nuermberger EL; Savic RM
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Andries K; Jarlier V
    PLoS One; 2011 Mar; 6(3):e17556. PubMed ID: 21408613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.
    Driver ER; Ryan GJ; Hoff DR; Irwin SM; Basaraba RJ; Kramnik I; Lenaerts AJ
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3181-95. PubMed ID: 22470120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
    Koo MS; Manca C; Yang G; O'Brien P; Sung N; Tsenova L; Subbian S; Fallows D; Muller G; Ehrt S; Kaplan G
    PLoS One; 2011 Feb; 6(2):e17091. PubMed ID: 21364878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters.
    Ahmad Z; Pinn ML; Nuermberger EL; Peloquin CA; Grosset JH; Karakousis PC
    J Antimicrob Chemother; 2010 Oct; 65(10):2172-5. PubMed ID: 20693172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.
    Fox L; Kramer MR; Haim I; Priess R; Metvachuk A; Shitrit D
    Eur J Clin Microbiol Infect Dis; 2011 Jul; 30(7):863-7. PubMed ID: 21431989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
    Sarathy JP; Via LE; Weiner D; Blanc L; Boshoff H; Eugenin EA; Barry CE; Dartois VA
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dosing regimens in the treatment of tuberculosis.
    Blom-Bülow B
    Scand J Infect Dis Suppl; 1990; 74():258-61. PubMed ID: 2129066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using animal models to develop new treatments for tuberculosis.
    Nuermberger E
    Semin Respir Crit Care Med; 2008 Oct; 29(5):542-51. PubMed ID: 18810687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
    Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
    Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.
    Walter K; Kokesch-Himmelreich J; Treu A; Waldow F; Hillemann D; Jakobs N; Lemm AK; Schwudke D; Römpp A; Hölscher C
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0158821. PubMed ID: 34871095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.